Champions Oncology, Inc. 2I3.F Stock
Champions Oncology, Inc. Price Chart
Champions Oncology, Inc. 2I3.F Financial and Trading Overview
| Champions Oncology, Inc. stock price | 4.54 EUR |
| Previous Close | 5 EUR |
| Open | 4.96 EUR |
| Bid | 5.05 EUR x 0 |
| Ask | 5.1 EUR x 0 |
| Day's Range | 4.96 - 4.96 EUR |
| 52 Week Range | 3.5 - 9.1 EUR |
| Volume | 200 EUR |
| Avg. Volume | 18 EUR |
| Market Cap | 69.04M EUR |
| Beta (5Y Monthly) | 0.87676 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.67 EUR |
2I3.F Valuation Measures
| Enterprise Value | 65.02M EUR |
| Trailing P/E | N/A |
| Forward P/E | 20.666668 |
| PEG Ratio (5 yr expected) | 9.9 |
| Price/Sales (ttm) | 1.2863048 |
| Price/Book (mrq) | 9.520153 |
| Enterprise Value/Revenue | 1.211 |
| Enterprise Value/EBITDA | -79.775 |
Trading Information
Champions Oncology, Inc. Stock Price History
| Beta (5Y Monthly) | 0.87676 |
| 52-Week Change | -28.057% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.1 EUR |
| 52 Week Low | 3.5 EUR |
| 50-Day Moving Average | 4.37 EUR |
| 200-Day Moving Average | 5.33 EUR |
2I3.F Share Statistics
| Avg. Volume (3 month) | 18 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 13.56M |
| Float | 4.89M |
| Short Ratio | N/A |
| % Held by Insiders | 24.05% |
| % Held by Institutions | 71.09% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | April 30, 2022 |
| Most Recent Quarter (mrq) | January 31, 2023 |
| Next Fiscal Year End | April 30, 2023 |
Profitability
| Profit Margin | -5.80% |
| Operating Margin (ttm) | -5.67% |
| Gross Margin | 47.06% |
| EBITDA Margin | -1.51% |
Management Effectiveness
| Return on Assets (ttm) | -5.45% |
| Return on Equity (ttm) | -38.25% |
Income Statement
| Revenue (ttm) | 53.68M EUR |
| Revenue Per Share (ttm) | 3.99 EUR |
| Quarterly Revenue Growth (yoy) | -3.20% |
| Gross Profit (ttm) | 25.48M EUR |
| EBITDA | -815000 EUR |
| Net Income Avi to Common (ttm) | -3118000 EUR |
| Diluted EPS (ttm) | -0.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.65M EUR |
| Total Cash Per Share (mrq) | 0.86 EUR |
| Total Debt (mrq) | 8.87M EUR |
| Total Debt/Equity (mrq) | 125.54 EUR |
| Current Ratio (mrq) | 0.979 |
| Book Value Per Share (mrq) | 0.521 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 5.46M EUR |
| Levered Free Cash Flow (ttm) | 4.11M EUR |
Profile of Champions Oncology, Inc.
| Country | Germany |
| State | NJ |
| City | Hackensack |
| Address | One University Plaza |
| ZIP | 07601 |
| Phone | 201 808 8400 |
| Website | https://www.championsoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 230 |
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Q&A For Champions Oncology, Inc. Stock
What is a current 2I3.F stock price?
Champions Oncology, Inc. 2I3.F stock price today per share is 4.54 EUR.
How to purchase Champions Oncology, Inc. stock?
You can buy 2I3.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Champions Oncology, Inc.?
The stock symbol or ticker of Champions Oncology, Inc. is 2I3.F.
Which industry does the Champions Oncology, Inc. company belong to?
The Champions Oncology, Inc. industry is Biotechnology.
How many shares does Champions Oncology, Inc. have in circulation?
The max supply of Champions Oncology, Inc. shares is 13.78M.
What is Champions Oncology, Inc. Price to Earnings Ratio (PE Ratio)?
Champions Oncology, Inc. PE Ratio is now.
What was Champions Oncology, Inc. earnings per share over the trailing 12 months (TTM)?
Champions Oncology, Inc. EPS is -0.66 EUR over the trailing 12 months.
Which sector does the Champions Oncology, Inc. company belong to?
The Champions Oncology, Inc. sector is Healthcare.